Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical Result for Patients Who Simultaneously Presented With Myasthenia Gravis and Thymoma.

Thoracic cancer·2026
Same author

Validity and reliability of on‑site and off‑site direct observation of procedural skills (DOPS) for knee mobilization in Physical therapy education.

The Journal of manual & manipulative therapy·2026
Same author

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

British journal of cancer·2026
Same author

Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer.

Therapeutic advances in medical oncology·2026
Same author

Quantitative and qualitative evaluation of residual deposits in implanted intravenous ports informs maintenance strategies.

Scientific reports·2026
Same author

Time-Dependent Association Between Prehospital Blood Pressure and Outcomes in Acute Spontaneous Intracerebral Hemorrhage.

European journal of neurology·2026

Related Experiment Video

Updated: May 9, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K

Integrating Pathologic Stage and Perioperative Circulating Tumor Cell Variations: Early Relapse Prediction Model for

Jui-Ying Fu1,2, Chih-Tsung Wen2,3, Ching-Feng Wu2,4

  • 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.

JCO Precision Oncology
|April 28, 2025
PubMed
Summary

Perioperative circulating tumor cell (CTC) changes can predict relapse in resectable non-small cell lung cancer (NSCLC). Specific CTC variations identified patients with no relapse risk or highest relapse risk, aiding treatment decisions.

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K

Related Experiment Videos

Last Updated: May 9, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K

Area of Science:

  • Oncology
  • Translational Research
  • Cancer Biomarkers

Background:

  • Preventing disease relapse is crucial for resectable non-small cell lung cancer (NSCLC) patients.
  • Circulating tumor cells (CTCs) are emerging biomarkers in cancer management.

Purpose of the Study:

  • To investigate the association between changes in perioperative CTC levels and disease relapse in resectable NSCLC.
  • To develop a predictive model for disease relapse based on CTC dynamics.

Main Methods:

  • Ninety-nine patients with resectable NSCLC were stratified into two cohorts based on lymph node metastasis (0-1a and 1b-4).
  • Perioperative CTC levels were measured and analyzed for correlation with disease-free survival.

Main Results:

  • In cohort 0-1a, specific CTC count differences indicated no disease relapse.
  • In cohort 1b-4, a CTC count difference ≥6.25 between postoperative days 3 and operation predicted the highest relapse risk, with all patients relapsing within 2 years.
  • Lower CTC differences in cohort 1b-4 were associated with relapses occurring within 2 years.

Conclusions:

  • A novel relapse prediction model using CTC variations effectively identified patients at no risk and highest risk of relapse.
  • These findings can guide clinicians in tailoring adjuvant treatment strategies for resectable NSCLC patients based on their relapse risk profile.